Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Summary

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.

Timeline

Start

2023-05-17

Primary completion

2024-05-27

Completion

2025-05-27

Publications

• Wang D, Wang X, Tan B, Wen X, Ye S, Wu Y, Cao X, Zhang X, Wang C, Geng L, Zhang H, Feng X, Zheng B, He Y, Liu M, Wu X, Du B, Sun L, Xu H. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med. 2025 Oct 10;6(10):100749. doi: 10.1016/j.medj.2025.100749. Epub 2025 May 29.
• Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024 Sep 5;187(18):4890-4904.e9. doi: 10.1016/j.cell.2024.06.027. Epub 2024 Jul 15.

Drugs

Indications